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Abstract
Background: The prevalence of nontuberculous mycobacterial (NTM) disease is rising. An understanding of known
risk factors for disease sheds light on the immunological and physical barriers to infection, and how and why they
may be overcome. This review focuses on human NTM infection, supported by experimental and in vitro data of
relevance to the practising clinician who seeks to understand why their patient has NTM infection and how to
further investigate.
Discussion: First, the underlying immune response to NTM disease is examined. Important insights regarding
NTM disease susceptibility come from nature's own knockouts, the primary immune deficiency disorders. We
summarise the current knowledge surrounding interferon-gamma (IFNγ)-interleukin-12 (IL-12) axis abnormalities,
followed by a review of phagocytic defects, T cell lymphopenia and rarer genetic conditions known to predispose
to NTM disease. We discuss how these define key immune pathways involved in the host response to NTM.
Iatrogenic immunosuppression is also important, and we evaluate the impact of novel biological therapies, as
well as bone marrow transplant and chemotherapy for solid organ malignancy, on the epidemiology and
presentation of NTM disease, and discuss the host defence dynamics thus revealed. NTM infection and
disease in the context of other chronic illnesses including HIV and malnutrition is reviewed. The role of
physical barriers to infection is explored. We describe how their compromise through different mechanisms
including cystic fibrosis, bronchiectasis and smoking-related lung disease can result in pulmonary NTM
colonisation or infection. We also summarise further associations with host factors including body habitus and age.
Summary: We use the presented data to develop an over-arching model that describes human host defences
against NTM infection, where they may fail, and how this framework can be applied to investigation in routine
clinical practice.
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Background
Nontuberculous mycobacteria have historically been
seen as environmental organisms of limited clinical
relevance, overshadowed by their more aggressive
cousin, Mycobacterium tuberculosis. It was not until
the HIV pandemic highlighted disseminated Mycobac-
terium avium and intracellulare as major opportunis-
tic infection syndromes that their significance was
recognised by the general healthcare community, a
role further cemented by the expansion of iatrogenic
immunosuppression. Evidence to support an ongoing
rise in disseminated NTM infection is limited [1].
This is not the case for chronic pulmonary NTM dis-
ease which is increasing [2] in part due to an aging,
vulnerable population [3, 4].
NTM are regarded generally as low pathogenicity
organisms, which can be transiently isolated from
samples such as sputum, colonise body sites such as
the lung, or cause persistent infection and disease.
Distinguishing between these different clinical states
can be surprisingly difficult. However, it is important
to do as this underpins both clinical management de-
cisions and predicts outcome. An accepted approach
is to define NTM-associated pulmonary disease as
that in which compatible clinical features occur in
people from whom NTM are repeatedly isolated over
time [5]. Treatment can be poorly tolerated and is
certainly less effective than that for tuberculosis (TB) [6].
Hence an understanding of who is at risk enables us to
both target interventions and potentially prevent disease
occurring.
Research into monogenic disorders conferring suscep-
tibility to disseminated NTM infection provides key in-
sights into the critical host immune responses against
these organisms, though many questions remain: in par-
ticular why such a large population of apparently im-
munocompetent people become infected and develop
pulmonary disease.
We present here a summary of how specific conditions
and iatrogenic interventions have elucidated both the
essential and redundant components of human de-
fences against NTM. We use this to suggest practical
strategies for investigation in patients presenting with
these infections.
Discussion
Lessons from primary immune deficiencies
CLINICAL VIGNETTE: A 2-year old boy born to first-
cousin parents presents with several weeks of fever, weight
loss, diarrhoea and skin nodules. Examination reveals
widespread lymphadenopathy and hepatosplenomegaly.
Blood cultures are positive for M. avium.
A number of monogenic disorders conferring suscepti-
bility to disseminated NTM infection are grouped
together as Mendelian Susceptibility to Mycobacterial
Disease (MSMD) conditions. Although extremely rare
[7] and predominantly affecting children, these diseases
offer insight into critical immune defences against
mycobacteria.
Cytokine pathway defects
The immune response to mycobacterial infection is
summarised in Box 1 and Figure 1, together with sites of
dysfunction due to primary immunodeficiency syn-
dromes. Essentially, defence is mediated by mononuclear
phagocytes’ ability to kill mycobacteria and secrete IL-12,
augmented by IFNγ-secreting lymphocytes (especially
CD4+ T cells).
Increased susceptibility to mycobacterial disease is
seen in several human genetic syndromes which result
from mutations in critical cytokine pathways affecting
IL-12β [8, 9], IL-12Rβ1 [10], IFNγR1 [11–13] and
IFNγR2 [14]. Mutations in the transcription factor
STAT1 [15–19] result in failure to respond to signals
from type I (IFNα/β), type II (IFNγ) or type III (IFNλ1/
2/3) interferons, and bring a dual risk of mycobacterial
and viral infections, as can deficiency of tyrosine kinase
2 (TYK2), a janus kinase widely active in cytokine signal-
ling. Loss of mycobacterial infection control in this latter
condition is caused by loss of the intracellular signalling
cascade triggered by IL-12 and mediated by the inter-
action of IL-12Rβ1 with TYK2 [20]. Mutations in inter-
feron regulatory factor (IRF)-8 [21] impair production of
IL-12 in response to IFNγ. Mutations in interferon-
stimulated gene (ISG)-15 [22] also confer susceptibility
to NTM: the gene product, interferon-induced 17 kDa
protein, is involved in IFNγ production by T and NK
cells. In some of these genetic syndromes, mycobacterial
Box 1. Summary of the key immune responses to
mycobacterial infection
Following internalisation of the mycobacterium, IL-12 is produced
by the infected mononuclear phagocyte. This binds to the IL-12
receptor on T or natural killer (NK) cells, which initiates an
intracellular signalling cascade culminating in IFNγ production.
The secreted IFNγ then binds to its receptor on the phagocyte
to signal via JAK-STAT pathways, resulting in macrophage
activation and further IL-12 release, in addition to tumour necrosis
factor alpha (TNFα) and interleukin 1 (IL-1). Activated macrophages
demonstrate enhanced phagosome maturation, increased killing
of intracellular pathogens and upregulated antigen presentation,
thereby activating Th1-phenotype T cells to proliferate and release
further IFNγ. The secreted TNFα plays a critical role in the
development of granulomas (reviewed in [112]).
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infection has been successfully treated with adjunctive
interferon administration [23–26].
Newly described mutations in RAR-related Orphan
Receptor C (RORC) predispose to mycobacterial in-
fection as well as mucocutaneous candidiasis. RORC
encodes the RORγ and RORγT isoforms of a tran-
scription factor involved in regulating immune func-
tion, cellular differentiation and metabolism. Although
susceptibility to candidiasis is due to disturbances in
the IL-17 pathway, the increased risk of mycobacterial
infection is again via impaired IFNγ responses (in this
instance from γδ T cells and CCR6+CXCR3+CD4+ αβ
Th1 cells) [27].
Deficiency of nuclear factor‐κB essential modulator
(NEMO) results in NTM susceptibility within the di-
verse phenotype of this X-linked condition, implicating
NF-κB signalling and by extrapolation the upstream
messenger TNF and/or signalling via Toll-like receptors
(TLRs) [28, 29].
Phagocyte defects
Defence against intracellular pathogens such as NTM
requires effective intracellular killing by phagocytes in-
cluding neutrophils, monocytes, macrophages and den-
dritic cells. In chronic granulomatous disease (CGD), the
respiratory burst - critical to phagocyte activation and
intracellular killing - is impaired by the lack of func-
tional NADPH oxidase.
A variable proportion of CGD patients (6-57 %, study-
dependent) develop local and/or systemic complications
following vaccination with bacillus Calmette-Guérin
(BCG) [30]. The importance of the macrophage respira-
tory burst in defence against mycobacteria is highlighted
by a mutation resulting in a reactive oxygen species
Fig. 1 The immune response to mycobacterial infection and known sites of dysfunction. Human genetic syndromes which affect the immune
response to mycobacterial infection are known to result from disorders in the following genes: ISG15, IL-12B, IL12RB1, IFNGR1, IFNGR2, STAT1,
IRF8, ISG-15, GATA2 and NADPH oxidase complex subunit genes such as CYBB. Nontuberculous mycobacteria (A) are phagocytosed (B), triggering
release of IL-12 (C), a heterodimeric cytokine formed from the gene products of IL12A and IL12B, which binds a receptor heterodimer (D)
of IL-12RB1 and IL-12RB2 on T cells and NK cells. Signalling to the nucleus mediated by TYK2 (E) then results in IFNγ production. IFN gamma binds its
receptor (F), a heterodimer of IFNGR1 and IFNGR2, triggering phosphorylation of JAK2, JAK1, and STAT1 (G). The resultant phosphorylated
STAT1 molecule homodimerises to form the pSTAT1 complex which translocates to the nucleus and binds the IFN gamma activating sequence.
This triggers transcription of interferon stimulated genes (ISG) via IRF8 (H), and increases IL12, TNFα, ISG15 (I), and potentiation of macrophage
activation. Activated macrophages demonstrate enhanced phagosome maturation and increased killing of intracellular pathogens, and
upregulated antigen presentation, thereby activating Th1-phenotype T cells to proliferate and release further IFNγ. TNFα drives development of
granulomas. IRF8 aids differentiation of myeloid progenitors into monocytes, and controls transcriptional responses of mature myeloid cells to
interferons (IFNs) and Toll-like receptor (TLR) agonists. NFκB is a rapid-acting transcription factor modulated by NEMO (J) and activated by
stimuli including signalling through CD40 (K), TLR (L), reactive oxygen species and TNFα. Activation allows a host of inflammatory and immune
responses, including IL12 release. Effective intraphagosomal killing through reactive oxygen species requires an intact NADPH oxidase complex (M).
Intact haematopoiesis of monocyte lineages is also required via GATA2 (N)
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formation defect in macrophages but not neutrophils
that is nevertheless still associated with susceptibility to
tuberculosis [31].
Intriguingly, although there is evidence from ex vivo
experiments that human neutrophils restrict the growth
of or kill many NTM species [32–34] and that neutro-
phils contribute to the control of M. avium in mice
[35–37], there is little to suggest that patients with
isolated neutrophil disorders or neutropenia have a
specifically increased risk of NTM infection.
Other primary immunodeficiency syndromes
Autosomal dominant deficiency of the transcription fac-
tor GATA-2 carries a significant risk of NTM infection
[38]. This disorder has a diverse presentation, such that
it may be diagnosed at any time from early infancy to
old age. Manifestations can vary from the asymptomatic
to near-lethal. Typical features include monocytopenia,
B and NK cell cytopenias, and myelodysplastic syn-
drome. Although multiple factors may contribute to
NTM susceptibility, including NK cell deficiency and
impaired cytokine release [39], the simplest explanation
is a deficiency of mononuclear phagocytes [40, 41].
Immunodeficiencies that profoundly affect the number
or function of T cells also predispose to NTM infection
(as well as many other pathogens). This includes Severe
Combined Immune Deficiency (SCID) [42] but also iso-
lated CD4+ T cell deficiency [43], which is associated
with both pulmonary and disseminated infection,
emphasising the importance of this T cell type.
Some primary immunodeficiencies are not associ-
ated with a significantly increased risk, including the
antibody-deficiency syndromes, such as Common
Variable Immunodeficiency (CVID) [44] and X-linked
Agammaglobulinaemia (XLA) [45]. The occasional
NTM infections which do occur in such patients are
generally associated with significant bronchiectasis - itself
an independent risk factor, as described later.
Interferon-γ autoantibodies
Another characterised immune defect affecting host
defence against NTM is anti-IFNγ autoantibody for-
mation [46, 47]. A cohort of NTM patients, fre-
quently of Asian origin and over 60 years old, have
been demonstrated to produce these antibodies [48–50].
Analysis typically demonstrates loss of IFNγ-mediated
augmentation of TNFα and STAT1 phosphorylation in
whole blood, which normalises when serum is removed,
consistent with the presence of inhibitory antibodies
against IFNγ [50]. Notably, patients with treatment-
refractory disseminated NTM infection and IFNγ auto-
antibodies have been successfully treated with anti-CD20
(Rituximab) and experienced sustained remission from in-
fection [51, 52].
Autoantibodies against IL-12 are also described, es-
pecially in association with thymoma [53]. These may
be expected to increase risk of NTM infection,
though their clinical significance remains unclear at
present. Importantly, autoantibodies including those
directed against cytokines, tend to be more prevalent
in older adults [54].
Immunological insights from NTM patients and
genome-wide associations
Many of the disorders discussed so far represent funda-
mental defects in key antimycobacterial pathways, and
often manifest as disseminated infection in young
people. However, older patients with isolated pulmonary
NTM (p-NTM) infection may have more subtle abnor-
malities of the same immunological processes, such as
impaired IFNγ (and often TNFα) production [55–57] in
stimulated whole blood or peripheral blood mono-
nuclear cells. There are also reports of clinical improve-
ment with the administration of IFNγ in patients with
pulmonary MAC infections [24, 58].
However, these findings are not consistently replicated:
in a prospective cohort study of 63 adults with p-NTM,
no significant abnormality of immune function was
found in the IL-12/IFNγ axis or numbers of lymphocyte
subsets [59]. Studies of other cytokines in NTM disease
including TGF-β, IL10, IL-17, and IL-18 reveal a differ-
ential balance relative to controls [60, 61]. This may in-
dicate that multiple subtle immunological abnormalities
co-exist in some patients that together increase overall
risk. In another example of this, a recent report found
an increased frequency of potentially significant poly-
morphisms in immune system genes (including IRF8
and STAT1) among NTM patients compared with their
relatives or healthy controls [62]. One gene where poly-
morphisms are enhanced in NTM is NRAMP1, whose
product improves resistance to intracellular pathogens
by decreasing intraphagosomal iron and increasing pro-
duction of inducible nitric oxide synthase (iNOS) [63].
Deleterious mutations in such a pathway would be con-
sistent with the core immunological defence against
mycobacteria: that is, a requirement for functional
mononuclear phagocytes (especially macrophages) to kill
mycobacteria, functional CD4+ T cells plus intact pro-
duction of, and response to, IFNγ, IL-12 and TNFα.
Beyond intrinsic defects in host immunity, there are
several other risks for NTM infection. These are sum-
marised in the following sections.
Systemic illness
CLINICAL VIGNETTE: A 35-year old patient with
significant graft-versus-host disease, eight weeks after
unrelated-donor stem cell transplant for acute myeloid
leukaemia, presents with fevers and malaise. Blood
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cultures from an indwelling central venous catheter are
positive for M.fortuitum.
A number of systemic illnesses increase the likelihood
of NTM infection. This association can generally be
understood in terms of the key immune responses de-
scribe above. For example, there is a clear and long-
established relationship between disseminated NTM
infection (especially M.avium/intracellulare) and HIV-1-
seropositivity, with the risk increasing sharply when the
CD4+ T cell count falls below 50/mm3 [64]. There is also
an increased risk of isolated pulmonary disease, espe-
cially with M.kansasii [65], whose pathogenicity and
clinical manifestations more closely resemble tubercu-
losis than other NTMs. Again, the CD4+ T cell count is
usually low [66].
Recipients of solid organ transplants are particularly
vulnerable to NTM, consistent with their broad disease-
related and iatrogenic immunosuppression [67–70].
Similarly, stem cell transplant recipients, who have a
profound deficiency of all lymphoid and myeloid cell
types, are at significantly increased risk of NTM infec-
tion. This includes rapid-growing species which can
cause central catheter infections [71]. Notably, the ma-
jority of infections probably occur outside periods of
neutropenia [72], again confirming relative redundancy
of neutrophils in NTM defence.
Other diseases, for example rheumatoid arthritis,
are associated with heightened risk of NTM. This
may relate to intrinsic T cell dysfunction [73] but also
to the use of immunosuppressive medications, associ-
ated lung disease or reduced leptin levels – all dis-
cussed below. Diabetes, which is an established risk
factor for TB [74] has, curiously, not been implicated
in NTM infection to date.
Iatrogenic immunosuppression
Targeted therapies
As described, TNFα is essential for granuloma forma-
tion. Correspondingly, there is a significant risk of devel-
oping either pulmonary or disseminated NTM infection
with anti-TNFα treatment [75]. An analysis of the
United States Food and Drugs Administration database
of adverse events associated with TNFα inhibitors re-
vealed over 100 confirmed and probable cases of NTM
infection in that population. The most common organ-
ism was Mycobacterium avium, and 44 % of cases dem-
onstrated extrapulmonary disease [76].
Other biologic and newer small molecule synthetic
therapies are less well studied, but theoretical risks –
based on their impact versus the key NTM defences
detailed above – are discussed in Box 2 and Table 1.
Those agents with high associated risk (++ or +++)
are more likely to predispose to disseminated NTM
disease than those with modest or low risk, although
concomitant immunocompromise from underlying condi-
tions or adjunctive treatments would compound the
effect of any agent. All implicated therapies may pre-
dispose to pulmonary infection, especially in patients
with structural lung disorders. Current best practice
for clinicians considering prescribing biologic im-
munosuppressive agents is to carry out a screen for
latent TB prior to initiating therapy. We suggest that
consideration should also be given to detecting NTM
infection (via sputum culture) prior to treatment with
high-risk molecules, especially in patients with under-
lying pulmonary disease.
Broadly acting immunosuppressive agents
Within the adult NTM disease patient population there
is a considerable burden of chronic respiratory disease
(discussed below). Inhaled and oral steroids are fre-
quently used for treatment of many of these conditions,
and a corresponding increased susceptibility to disease is
found. In a Danish population-based study of respiratory
disease, use of inhaled corticosteroids in COPD in-
creased the odds ratio for p-NTM disease from 7.6 to
19.6, and a dose-risk response was noted with increasing
doses [77]. A relationship with steroids and rising NTM
disease risk is also seen in the treatment of rheumatoid
arthritis [78] and asthma [79].
NTM disease has been associated with immunosup-
pressive medications such as azathioprine, cyclophos-
phamide, mycophenolate and cyclosporine, as well as
with anti-TNFα agents [78]. Again, clinicians should
consider screening for NTM before starting these drugs
and remain vigilant for infection and disease during
treatment.
Structural lung disease
CLINICAL VIGNETTE: A 76 male smoker with known
COPD was investigated for new changes on his chest
radiograph associated with increased sputum and a
gradual reduction in his exercise capacity. He had not
responded to several short courses of antibacterials. Spu-
tum cultures isolated M. xenopi with no initial evidence
for underlying lung neoplasia.
Discussion thus far has focussed on immunological
defences against NTM infection, but it is clear that
the physical barriers integral to healthy lungs are also
critical. In p-NTM disease case series, chronic re-
spiratory diseases such as bronchiectasis and COPD
are common associations. Equally, NTM prevalence
in bronchiectasis is high [80] - estimated at 9.3 % ac-
cording to a recent meta-analysis [81]. Given that
lung damage, such as cavitation or bronchiectasis, is
often regarded as an integral component of p-NTM
disease diagnosis [5], it can be difficult to determine
whether lung structural changes predispose to, or
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arise as a consequence of, p-NTM disease. Although
non-CF bronchiectasis is a diverse entity with mul-
tiple aetiologies, a unifying patho-mechanism is pro-
vided by Cole’s vicious cycle model [82] where local
pulmonary damage results in non-clearing infection
that leads to an excessive inflammatory response, with
consequent further lung damage (dilatation and de-
struction, i.e. bronchiectasis) and more infection.
The complexity of predisposition to p-NTM disease is
demonstrated by a whole-exome sequencing study of 69
immunocompetent p-NTM disease patients and 18 un-
affected family members. This revealed that patients
with p-NTM have more low-frequency, protein-affecting
variants in immune, cystic fibrosis transmembrane con-
ductance regulator (CFTR), cilia, and connective tissue
genes than their unaffected family members and control
subjects [62], demonstrating the complexity of predis-
position to NTM disease.
Chronic obstructive pulmonary disease
COPD is a chronic, progressive lung disease charac-
terised by airflow limitation with poor reversibility.
Lung injury, triggered most often by smoking, causes
inflammation, tissue destruction and remodelling of
elastin and collagen, with occlusion of small airways
by narrowing, obliteration and mucus plugs [83], The
heightened susceptibility to infection was demon-
strated in a prospective cohort of COPD exacerba-
tions where 22 % of subjects were culture-positive for
NTM [84]. The extent to which NTM infection itself
Box 2. Risk for NTM infection from monoclonal antibodies and small molecule medications
Anti-cytokine/cytokine signalling medications
Of significant theoretical concern is the IL-12/23 inhibitor ustekinumab, given the central role of this cytokine in combating mycobacteria;
a report has been published of TB reactivation [113], but further data are required. The JAK pathway inhibitors tofacitinib and ruxolitinib
interfere with interferon signalling (as described earlier) and should also therefore carry a significant risk. Tofacitinib appears to carry a
similar risk of TB to anti-TNF agents [114] and disseminated TB on ruxolitinib is described [115]. Data are currently scarce on these agents,
but the immunological basis of risk for NTM infection is clear.
B cell targeted therapies
Although cases of NTM infection have been associated with the anti-CD20 monoclonal rituximab, reports remain rare and are usually in
patients receiving other immunosuppressives [116], while the risk of TB is not significantly increased [114]. This is consistent with a
relatively minor role for B cells and antibodies in host defence against mycobacteria. However, clinicians should be aware that
hypogammaglobulinemia secondary to B cell-targeted therapies will increase risk of bronchiectasis and thereby colonisation or
infection with NTM.
Anti-inflammatory agents
The anti-IL-6 agent tocilizumab and CTLA-4 agonist abatacept (which reduces co-stimulation from antigen-presenting cells to T cells)
both impair Th1 responses and might be expected to modestly increase risk of mycobacterial infection. Preliminary data may support
some risk of NTM, at least for tocilizumab [116, 117]; correspondingly, the incidence of TB is increased modestly with both agents but
not to the level seen with TNFα blockade [114]. Molecules which interfere with the IL-1 axis (anakinra and rilonacept) similarly interrupt
inflammatory responses and may modestly increase risk of NTM infection. The α4-integrin component is expressed on many leucocytes
including lymphocytes and mononuclear phagocytes: the inhibitor natalizumab interferes with their migration and might increase risk of
infection – as has been reported [118].
Drugs used in malignancies and organ transplantation
It is probably less useful to consider specific risks of agents used for malignancies and in organ transplant due to the profoundly
immunosuppressive effects of the underlying conditions and adjunctive treatments. Nevertheless, molecules acting against T cell
and/or mononuclear phagocyte receptors such as CD25/IL-2R (eg daclizumab, basiliximab), CD3 (muromonab) or CD52 (alemtuzumab)
would all be expected to increase the risk, whereas those targeting growth factors or tissue-specific antigens would not.
Others
Denosumab inhibits RANKL, expressed on T helper cells and involved in differentiation of some mononuclear phagocytes, and thus may
be expected to increase risk although there is no supporting data so far. This is important to establish as the population more likely to
have osteoporosis (elderly women) are also at increased risk of NTM infection. In contrast, some agents target elements of the immune
system not involved in defences against NTM, such as omalizumab (anti-IgE) or eculizumab (anti-complement component C5) and
should not be associated with NTM infection.
Lake et al. BMC Medicine  (2016) 14:54 Page 6 of 13
may promote COPD has been investigated, and might
partly explain the apparent high frequency of reported
mycobacterial isolation [85]. Both bronchiectasis and
COPD are characterised by neutrophilic inflammation
[86, 87]. As described previously, this cell type is probably
not central to NTM defence, but instead can cause host
damage via the release of cytotoxic contents and thereby
further compromise physical barriers to infection.
Table 1 Potential effects of targeted small molecule/monoclonal agents on risk of NTM Infection
Element of NTM immune response targeted?
Target Example(s) T cells Mononuclear phagocytes Key cytokines Other Th1 cytokines Theoretical risk for NTM †
TNF Infliximab
Certolizumab
Adalimumab
Etanercept
Golimumab
N N Y N +++
IL-12/23 Ustekinumab N N Y N +++
JAK Ruxolitinib
Tofacitinib
? Y Y N +++
CD52 Alemtuzumab Y Y N ? ++
CD25/IL2R Basiliximab
Daclizumab
Y ? N ? ++
CD3 Muromonab Y N N N ++
α4-integrin component Natalizumab Y Y N N ++
IL-6R Tocilizumab N N N Y +
CTLA-4 (agonist) Abatacept
Belatacept
N Y ? Y +
IL-1R1/IL-1β Anakinra
Rilonacept
N N N Y +
CD30 Brentuximab Y N N N ±
RANKL Denosumab Y Y N N ±
CD20 Rituximab *
Ofatumumab *
N N N N -
BLyS/BAFF Belimumab * N ? N N -
Btk Ibrutinib * N ? N N -
HER-2/erbB Trastuzumab
Pertuzumab
Erlotinib
N N N N -
VEGF/VEGFR Bevacizumab
Ranibizumab
Aflibercept
Axitinib
Lapatinib
N N N N -
EGFR Panitumumab
Afatinib
Gefitinib
N N N N -
BcrAbl Bosutinib
Nilotinib
N N N N -
C5 Eculizumab N N N N -
IgE Omalizumab N N N N -
GPIIb/IIIa Abciximab N N N N -
* Target B cells – note risk of hypogammaglobulinemia and secondary bronchiectasis
† +++ very significant risk, ++ significant risk, + some risk, ± unclear risk, − no risk
Y = Yes, N = No, ? = possible
TNF, tumour necrosis factor; IL, interleukin; JAK, Janus activated kinase; CD, cluster of differentiation; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; RANKL,
Receptor activator of nuclear factor kappa-B ligand; BLyS, B lymphocyte stimulator; BAFF, B cell activating factor; Btk, Bruton’s tyrosine kinase; HER-2, Human
epidermal growth factor receptor 2; VEGF(R), vascular endothelial growth factor (receptor); EGFR, epidermal growth factor receptor; C5, complement component
C5; IgE, Immunoglobulin E; GPIIb/IIIa, Glycoprotein IIb/IIIa; NTM, nontuberculous mycobacteria; Th1, T helper 1
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Cystic fibrosis
Specific mutations in the CFTR gene, most commonly
the delta-F508 mutation, lead to defective function of
the cyclic-AMP stimulated chloride channel in the
membrane of epithelial cells and the clinical disease of
cystic fibrosis (CF). Homozygosity for these mutations
results in disordered sodium and chloride transport
across the epithelium with thickened respiratory secre-
tions. The heightened risk of pulmonary infection is well
established, and has a complex aetiology ranging from
impaired mucociliary function and viscous, inspissated
secretions, to compromise of many immunological de-
fences [88].
The predisposition to NTM infection is striking: CF
respiratory cultures exhibit a 10,000 fold greater preva-
lence of NTM than the general population, with the
most common being Mycobacterium avium complex
(MAC) and M. abscessus [89]. The importance of study-
ing this population is highlighted by the reported trans-
missibility of M. abscessus from patient to patient [90].
The implication of this for people at high risk of NTM
disease using healthcare services with other NTM pa-
tients is considerable. Importantly, there are an increas-
ing number of reported CFTR polymorphisms that do
not result in frank CF but nonetheless may predispose
to bronchiectasis and NTM infection [62, 91–93].
Other associations with structural lung disease are
summarised in Box 3. In all of these cases, it remains
difficult to determine how much of the NTM colonisa-
tion, infection and disease relate to anatomical changes
and secretions that are hard to clear, and how much
to associated dysregulated immune and inflammatory
responses.
Other host traits as risk factors for NTM infection
Aging appears to increase susceptibility to p-NTM dis-
ease (the mean age at presentation in a US study was
68.2 years [94]). Age greater than 65 is also associated
with worse outcomes (hazard ratio for death 9.17, 95 %
confidence interval 4.98-16.86 [95]). Whilst this may
simply reflect the fact that predisposing factors for NTM
infection, such as structural lung disease, are more
common with age, immunosenescence [96–99] affecting
key host defences (especially T cell function) may also be
important.
Many p-NTM prevalence studies reveal a greater
number of female than male patients [2, 59, 100]; fe-
males with non-CF bronchiectasis seem to be at particu-
larly high risk [80]. A possible explanation may be the
lower levels of oestrogen in post-menopausal females, as
experiments in ovariectomised mice show that oestrogen
enhances the clearance of MAC [101], albeit human data
are inconclusive [102, 103].
Low body mass index (BMI) appears to be a risk factor
for NTM infection, with a protective effect seen at
higher BMIs [55, 104, 105]. Lower levels of subcutane-
ous fat are present in p-NTM patients compared to con-
trols [106]. It has been suggested that the adipokines
leptin and adiponectin may be responsible. Leptin, a
hormone expressed by white fat cells and whose levels
positively correlate with body fat, regulates satiety but
also has immunomodulatory effects such as driving T
cell differentiation towards a Th1 IFNγ-producing
phenotype, enhancing phagocyte function and increasing
TNF and IL-12 secretion [55]. Leptin deficient mice
(ob/ob) mice have delayed clearance of Mycobacterium
abscessus lung infection compared to wild-type mice
[107]. Conversely, adiponectin is a protein that has a
role in fatty acid oxidation and inversely correlates
with body fat; this adipokine has immunosuppressive
effects on Th1 responses [104].
P-NTM disease has been reported in a patient group
characterised by greater than average height, thoracic
skeletal abnormalities and mitral valve prolapse [59].
The evidence that this is related to an underlying
connective tissue disorder is currently limited [108].
However, abnormalities of the thoracic skeleton such
as scoliosis and pectus excavatum do appear to be
more common than in patients with TB or the gen-
eral population [105, 109].
Severe vitamin D deficiency appears to be associated
with p-NTM disease [110], although the mechanism
remains less clear than for M.tuberculosis [111].
Summary
NTM are increasingly isolated from respiratory secre-
tions, and this appears to reflect a rise in true disease.
Analysis of immune function and host phenotype reveals
the fundamental mechanisms of successful host defence
against NTM. These are an intact IFNγ-IL-12 axis, ef-
fective phagocytosis and intracellular killing, adequate
monocyte haemopoiesis and circulating CD4+ T cell
numbers, plus an undamaged pulmonary epithelium
with effective clearance of secretions. Most NTM lung
disease occurs in older patients. At our current level of
knowledge, the largest patient population, i.e. people
Box 3. Structural lung diseases associated with
pulmonary NTM
Alpha-1 antitrypsin [119]
COPD
Cystic Fibrosis
Non-CF Bronchiectasis
Pneumoconiosis [77, 120, 121]
Pulmonary alveolar proteinosis [122]
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Fig. 2 Systemic factors predisposing to NTM disease. Apparently ‘immunocompetent’ individuals may have an elevated risk of NTM disease due
to structural lung disease or specific host features such as advanced age, female gender or polymorphisms of immune, cilia, connective tissue or
CFTR genes. Immunocompromise causing susceptibility to NTM disease can be caused by primary immune deficiency, drugs targeting the
immune system such as anti-TNFα reagents, or systemic disease
Fig. 3 Flowchart for investigation of adult patients presenting with NTM disease
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with isolated lung disease, appear to have minimal
evidence for clear-cut, underlying immune defects. How-
ever, a small but important group will have demon-
strable and relevant alterations in their ability to control
NTM infection. Furthermore, subtle immune perturba-
tions may combine with lung damage to increase the
overall risk of NTM infection and disease.
Figure 2 summarises the elements described in this
article. Many of these risks are predictable and modifi-
able: clinicians and patients alike should strive to avoid
NTM infection as its treatment is prolonged and associ-
ated with considerable morbidity [5].
The degree to which investigations are performed
to identify these risks depends on the patient’s clinical
features and resources available. Figure 3 lists our ad-
vice for the investigation of adult patients presenting
with NTM infection. Children or anyone presenting
with apparently unexplained disseminated infection
should be referred to a clinical immunologist and
undergo whole exome sequencing if no defined sus-
ceptibility is identified; the pathway for investigating
early-onset MSMD conditions has been described
elsewhere [69].
All adult patients should be offered HIV testing and
assessed for underlying disease leading to immune com-
promise. A careful drug history should include biologics
or other therapies whose most recent administration
may have been weeks or months previously. Vitamin D
deficency is an easily reversible risk factor.
Clinicians should be aware in particular of the
haematological characteristics of GATA-2 deficiency
(monocytopenia, NK and B cell cytopenias), due to its
protean manifestations and wide range of age at first
presentation. Lymphocyte subsets help to identify this
pattern as well as idiopathic CD4 lymphopenia.
In pulmonary infection, the wide availability of high
resolution CT lung scanning at an acceptable radiation
dosage means that this is now an important component
of p-NTM work-up. Lung function tests will help to
identify COPD in patients without a pre-existing diagno-
sis, and also serve as a baseline for future management.
We advocate testing immunoglobulins in patients with
bronchiectasis to exclude an immunological basis for the
structural lung disease, even though hypogammaglobuli-
nemia is not a particular risk for NTM infection itself.
Patients with significant bronchiectasis should be inves-
tigated for underlying CF.
If no abnormalities are identified via these tests
then we advocate assessing for response to, and re-
lease of, IFNγ and IL-12. Defects in these pathways
can present clinically at a later age, and the tests can
inform whether IFNγ may be a treatment adjunct
worth considering. Anti-cytokine antibodies are more
common in older patients and should be measured; if
present, consideration may be given to immunomodu-
latory therapy (i.e. rituximab). T cell proliferation and
assays for CGD should be considered if there is a
compatible history, especially of other opportunistic
infections.
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